Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
Category:
Corporate/Financial News
Download
PDF Format (opens in new window)
Data from proof-of-concept, randomized, Phase 2 RELATIVITY-104 trial exploring the combination of nivolumab, relatlimab (1:1) and chemotherapy as first-line treatment...
Zur Pressemeldung auf news.bms.com